VIORA and BioTeke Partner for Saliva Pregnancy Tests
The companies are expanding their collaboration to bring rapid, non-invasive saliva-based pregnancy testing to international markets.
Updated on Oct. 28, 2026 in Pregnancy
Live Poll
Would you prefer a saliva-based pregnancy test over traditional urine-based testing for your home use?
VIORA and BioTeke have formed a new strategic partnership to manufacture and distribute saliva-based pregnancy tests globally. This collaboration aims to meet growing consumer demand for non-invasive testing solutions.
Why it matters
The move seeks to simplify the pregnancy testing process by replacing traditional urine samples with rapid saliva-based technology. This shift aims to improve accessibility and user comfort for individuals seeking health diagnostics.
The new test provides results in 20 seconds under specified conditions. VIORA holds exclusive commercial rights across 8 international markets.
The players
VIORA
A health technology company responsible for defining commercialization strategies and managing product distribution.
BioTeke
A manufacturer and technology provider that produces the diagnostic hardware at its facilities in China.
The details
VIORA provides the commercial strategy and distribution network while BioTeke handles the technology and manufacturing at facilities in China. The companies are currently finalizing packaging and supply chains to support their planned rollout, focusing heavily on regions within Europe.
Timeline
October 21, 2026: The companies formally signed the expansion agreement.
October 2026: VIORA leadership completed a visit to BioTeke manufacturing facilities.
November 16-19, 2026: The partners will showcase the technology at MEDICA 2026 in Düsseldorf, Germany.
Culture Shift
This development reflects a broader societal movement toward non-invasive home diagnostics that replace traditional, often less convenient, testing methods. It represents a significant step in the commercialization of saliva-based diagnostic testing platforms.
Users can expect a more discreet and faster testing experience compared to traditional urine-based kits. The product will be distributed through retail pharmacies, healthcare wholesale channels, and e-commerce platforms.
The takeaway
This partnership highlights the industry transition toward rapid diagnostic tools that prioritize user convenience and non-invasive procedures. Consumers should look for new, faster testing options as these products reach international retail markets in the coming months.
What happens next
The companies will showcase the technology and coordinate further international expansion plans at the MEDICA 2026 exhibition held in Germany from November 16 to 19, 2026.
Further reading
For more on the latest developments in home testing, visit the Pregnancy section.
More information
To connect with the team during the upcoming trade event, Schedule a meeting at MEDICA 2026.
Source note: This article includes information reported by Greatreporter -.
Live Poll
Would you prefer a saliva-based pregnancy test over traditional urine-based testing for your home use?
